Imatinib mesylate-gleevec® is considered a major alternative for the treatment of chronic myelogenous leukemia. Clinical studies demonstrate a complete hematological response in most patients treated with this drug. The effectiveness of the drug, the high cost and the patent expiration has been responsible for the publication of numerous studies that seek to improve the synthesis of this drug. This study reports an optimization of the first synthetic process described in the literature. Batches were synthesized on a semi-pilot scale, to develop methodologies that may be available for the production of the product on an industrial scale.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.